Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1 Negative”

144 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 144 results

Early research (Phase 1)Ended earlyNCT02936102
What this trial is testing

FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerChordoma and Alveolar Soft Part Sarcoma
Novartis Pharmaceuticals 154
Testing effectiveness (Phase 2)WithdrawnNCT05539365
What this trial is testing

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)Ended earlyNCT04489940
What this trial is testing

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Neoplasms
EMD Serono Research & Development Institute, Inc. 11
Early research (Phase 1)Ended earlyNCT03292172
What this trial is testing

Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Who this might be right for
Advanced Ovarian CancerTriple Negative Breast Cancer
Hoffmann-La Roche 36
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07134556
What this trial is testing

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

Who this might be right for
Triple Negative Breast CancerPDL-1 Positive
MedSIR 25
Large-scale testing (Phase 3)Looking for participantsNCT06103864
What this trial is testing

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 625
Testing effectiveness (Phase 2)Study completedNCT02628132
What this trial is testing

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Who this might be right for
Breast Cancer
King Faisal Specialist Hospital & Research Center 22
Testing effectiveness (Phase 2)Ended earlyNCT04260802
What this trial is testing

Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Who this might be right for
CancerNeoplasmsMetastatic Cancer+16 more
Ocellaris Pharma, Inc. 73
Testing effectiveness (Phase 2)UnknownNCT05266937
What this trial is testing

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Who this might be right for
Metastatic Breast CancerTriple Negative Breast CancerPD-L1 Gene Mutation
Consorzio Oncotech 49
Early research (Phase 1)Study completedNCT03396445
What this trial is testing

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Who this might be right for
PharmacokineticsSolid TumorCarcinoma, Non-Small-Cell Lung+1 more
Merck Sharp & Dohme LLC 182
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07459738
What this trial is testing

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Shanghai Henlius Biotech 60
Testing effectiveness (Phase 2)Study completedNCT02489448
What this trial is testing

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Yale University 68
Early research (Phase 1)Study completedNCT03430518
What this trial is testing

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Who this might be right for
HER2-Negative Metastatic Breast CancerRecurrent Ovarian Cancer
Amy Tiersten 9
Testing effectiveness (Phase 2)Study completedNCT03797326
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerOvarian Cancer+5 more
Merck Sharp & Dohme LLC 611
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 25
Large-scale testing (Phase 3)Study completedNCT04799249
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Who this might be right for
TNBC - Triple-Negative Breast CancerBreast Cancer
G1 Therapeutics, Inc. 194
Very early researchStudy completedNCT03911453
What this trial is testing

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

Who this might be right for
Breast Cancer
University of Arizona 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06229067
What this trial is testing

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 182
Testing effectiveness (Phase 2)WithdrawnNCT05879484
What this trial is testing

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Who this might be right for
Sinonasal CancerSquamous Non-small Cell Lung CancerLung Cancer+3 more
National Cancer Institute (NCI)
Load More Results